CoChat
Sign Up
Cited by 45Dermatological and Skeletal DisordersParathyroid Disorders and TreatmentsBone health and osteoporosis research

The Role of Sclerostin in Bone and Ectopic Calcification

Open access
De Maré, Annelies, D’Haese, Patrick C., Verhulst, Anja·2020·International Journal of Molecular Sciences
DOI 10.3390/ijms21093199PMC PMC7246472
Open this paper in CoChat — free accountOpen PDF

Abstract

Sclerostin, a 22-kDa glycoprotein that is mainly secreted by the osteocytes, is a soluble inhibitor of canonical Wnt signaling. Therefore, when present at increased concentrations, it leads to an increased bone resorption and decreased bone formation. Serum sclerostin levels are known to be increased in the elderly and in patients with chronic kidney disease. In these patient populations, there is a high incidence of ectopic cardiovascular calcification. These calcifications are strongly associated with cardiovascular morbidity and mortality. Although data are still controversial, it is likely that there is a link between ectopic calcification and serum sclerostin levels. The main question, however, remains whether sclerostin exerts either a protective or deleterious role in the ectopic calcification process.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21093199

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osteocytes control osteoclast activity by secreting sclerostin, which increases bone resorption by downregulating osteoblast OPG production and decreases osteoblastogenesis by inhibiting Wnt/β-catenin signaling pathways in osteoblast precursors.

    “Osteocytes control osteoclast activity by secreting sclerostin, which increases bone resorption by downregulating osteoblast OPG production and decreases osteoblastogenesis by inhibiting Wnt/β-catenin signaling pathways in osteoblast precursors [53].”

    From Osteoclasts and Microgravity (2020) · cites this paper as [53]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 171

  1. [1]Truswell A.S. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg’s disease J. Bone Joint Surg. Br. 1958 40 209 218 13539104
  2. [2]Buchem V. Hyperostosis corticalis generalisata familiaris (van Buchem’s disease) Acta Radiol. 1955 44 109 120 10.3109/00016925509170789 13258333 · DOI
  3. [3]Beighton P. Barnard A. Hamersma H. van der Wouden A. The syndromic status of sclerosteosis and van Buchem disease Clin. Genet. 1984 25 175 181 10.1111/j.1399-0004.1984.tb00481.x 6323069 · DOI
  4. [4]Van Hul W. Balemans W. Van Hul E. Dikkers F.G. Obee H. Stokroos R.J. Hildering P. Vanhoenacker F. Van Camp G. Willems P.J. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21 Am. J. Hum. Genet. 1998 62 391 399 10.1086/301721 9463328 PMC1376897 · DOI
  5. [5]Balemans W. Van Den Ende J. Freire Paes-Alves A. Dikkers F.G. Willems P.J. Vanhoenacker F. de Almeida-Melo N. Alves C.F. Stratakis C.A. Hill S.C. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21 Am. J. Hum. Genet. 1999 64 1661 1669 10.1086/302416 10330353 PMC1377909 · DOI
  6. [7]Brunkow M.E. Gardner J.C. Van Ness J. Paeper B.W. Kovacevich B.R. Proll S. Skonier J.E. Zhao L. Sabo P.J. Fu Y. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am. J. Hum. Genet. 2001 68 577 589 10.1086/318811 11179006 PMC1274471 · DOI · Paper page
  7. [8]Balemans W. Patel N. Ebeling M. Van Hul E. Wuyts W. Lacza C. Dioszegi M. Dikkers F.G. Hildering P. Willems P.J. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease J. Med. Genet. 2002 39 91 97 10.1136/jmg.39.2.91 11836356 PMC1735035 · DOI · Paper page
  8. [9]Staehling-Hampton K. Proll S. Paeper B.W. Zhao L. Charmley P. Brown A. Gardner J.C. Galas D. Schatzman R.C. Beighton P. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population Am. J. Med. Genet. 2002 110 144 152 10.1002/ajmg.10401 12116252 · DOI
  9. [10]Loots G.G. Kneissel M. Keller H. Baptist M. Chang J. Collette N.M. Ovcharenko D. Plajzer-Frick I. Rubin E.M. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease Genome Res. 2005 15 928 935 10.1101/gr.3437105 15965026 PMC1172036 · DOI · Paper page
  10. [11]van Lierop A.H. Hamdy N.A. van Egmond M.E. Bakker E. Dikkers F.G. Papapoulos S.E. Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers J. Bone Miner. Res. 2013 28 848 854 10.1002/jbmr.1794 23074140 · DOI
  11. [12]Tanaka S.S. Kojima Y. Yamaguchi Y.L. Nishinakamura R. Tam P.P. Impact of WNT signaling on tissue lineage differentiation in the early mouse embryo Dev. Growth Differ. 2011 53 843 856 10.1111/j.1440-169X.2011.01292.x 21762130 · DOI
  12. [13]Nusse R. Varmus H. Three decades of Wnts: A personal perspective on how a scientific field developed Embo J. 2012 31 2670 2684 10.1038/emboj.2012.146 22617420 PMC3380217 · DOI
  13. [14]Kang S. Bennett C.N. Gerin I. Rapp L.A. Hankenson K.D. MacDougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma J. Biol. Chem. 2007 282 14515 14524 10.1074/jbc.M700030200 17351296 · DOI
  14. [15]Bennett C.N. Longo K.A. Wright W.S. Suva L.J. Lane T.F. Hankenson K.D. MacDougald O.A. Regulation of osteoblastogenesis and bone mass by Wnt10b Proc. Natl Acad Sci USA 2005 102 3324 3329 10.1073/pnas.0408742102 15728361 PMC552924 · DOI
  15. [16]Robling A.G. Niziolek P.J. Baldridge L.A. Condon K.W. Allen M.R. Alam I. Mantila S.M. Gluhak-Heinrich J. Bellido T.M. Harris S.E. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin J. Biol. Chem. 2008 283 5866 5875 10.1074/jbc.M705092200 18089564 · DOI · Paper page
  16. [17]Bellido T. Ali A.A. Gubrij I. Plotkin L.I. Fu Q. O’Brien C.A. Manolagas S.C. Jilka R.L. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis Endocrinology 2005 146 4577 4583 10.1210/en.2005-0239 16081646 · DOI
  17. [18]Keller H. Kneissel M. SOST is a target gene for PTH in bone Bone 2005 37 148 158 10.1016/j.bone.2005.03.018 15946907 · DOI
  18. [19]Fujita K. Roforth M.M. Demaray S. McGregor U. Kirmani S. McCready L.K. Peterson J.M. Drake M.T. Monroe D.G. Khosla S. Effects of Estrogen on Bone mRNA Levels of Sclerostin and Other Genes Relevant to Bone Metabolism in Postmenopausal Women J. Clin. Endocr. Metab. 2014 99 E81 E88 10.1210/jc.2013-3249 24170101 PMC3879677 · DOI
  19. [20]Boudin E. Yorgan T. Fijalkowski I. Sonntag S. Steenackers E. Hendrickx G. Peeters S. De Mare A. Vervaet B. Verhulst A. The Lrp4 R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans J. Bone Miner. Res. 2017 32 1739 1749 10.1002/jbmr.3160 28477420 · DOI
  20. [21]Gong Z. Niklason L.E. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs) FASEB J. 2008 22 1635 1648 10.1096/fj.07-087924 18199698 PMC2605790 · DOI
  21. [22]Oswald J. Boxberger S. Jorgensen B. Feldmann S. Ehninger G. Bornhauser M. Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro Stem Cells 2004 22 377 384 10.1634/stemcells.22-3-377 15153614 · DOI
  22. [23]Thouverey C. Caverzasio J. Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/beta-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro Bonekey Rep. 2015 4 10.1038/bonekey.2015.126 26587226 PMC4635862 · DOI
  23. [24]Padhi D. Jang G. Stouch B. Fang L. Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J. Bone Miner. Res. 2011 26 19 26 10.1002/jbmr.173 20593411 · DOI
  24. [25]Martin A. David V. Laurence J.S. Schwarz P.M. Lafer E.M. Hedge A.M. Rowe P.S.N. Degradation of MEPE, DMP1, and release of SIBLING ASARM-Peptides (Minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP Endocrinology 2008 149 1757 1772 10.1210/en.2007-1205 18162525 PMC2276704 · DOI · Paper page
  25. [26]Rowe P.S.N. de Zoysa P.A. Dong R. Wang H.R. White K.E. Econs M.J. Oudet C.L. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia Genomics 2000 67 54 68 10.1006/geno.2000.6235 10945470 · DOI
  26. [27]Rowe P.S.N. The wrickkened pathways of FGF23, MEPE and PHEX Crit Rev. Oral. Biol. M 2004 15 264 281 10.1177/154411130401500503 15470265 PMC3361894 · DOI
  27. [28]Guo R. Rowe P.S.N. Liu S.G. Simpson L.G. Xiao Z.S. Quarles L.D. Inhibition of MEPE cleavage by Phex Biochem. Bioph. Res. Co. 2002 297 38 45 10.1016/S0006-291X(02)02125-3 12220505 · DOI
  28. [29]Rowe P.S.N. Kumagai Y. Gutierrez G. Garrett I.R. Blacher R. Rosen D. Cundy J. Navvab S. Chen D. Drezner M.K. MEPE has the properties of an osteoblastic phosphatonin and minhibin Bone 2004 34 303 319 10.1016/j.bone.2003.10.005 14962809 PMC3357088 · DOI
  29. [30]Atkins G.J. Rowe P.S. Lim H.P. Welldon K.J. Ormsby R. Wijenayaka A.R. Zelenchuk L. Evdokiou A. Findlay D.M. Sclerostin Is a Locally Acting Regulator of Late-Osteoblast/Preosteocyte Differentiation and Regulates Mineralization Through a MEPE-ASARM-Dependent Mechanism J. Bone Miner. Res. 2011 26 1425 1436 10.1002/jbmr.345 21312267 PMC3358926 · DOI
  30. [31]Kogawa M. Khalid K.A. Wijenayaka A.R. Ormsby R.T. Evdokiou A. Anderson P.H. Findlay D.M. Atkins G.J. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size Am. J. Physiol. Cell Ph. 2018 314 C53 C61 10.1152/ajpcell.00175.2017 28978523 PMC5866382 · DOI
  31. [32]Krause C. Korchynskyi O. de Rooij K. Weidauer S.E. de Gorter D.J.J. van Bezooijen R.L. Hatsell S. Economides A.N. Mueller T.D. Lowik C.W.G.M. Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways J. Biol. Chem. 2010 285 41614 41626 10.1074/jbc.M110.153890 20952383 PMC3009889 · DOI
  32. [33]Chandra A. Lin T. Young T. Tong W. Ma X.Y. Tseng W.J. Kramer I. Kneissel M. Levine M.A. Zhang Y.J. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms J. Bone Miner. Res. 2017 32 360 372 10.1002/jbmr.2996 27635523 PMC5476363 · DOI
  33. [34]Sutherland M.K. Geoghegan J.C. Yu C.P. Turcott E. Skonier J.E. Winkler D.G. Latham J.A. Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation Bone 2004 35 828 835 10.1016/j.bone.2004.05.023 15454089 · DOI
  34. [35]Karsdal M.A. Larsen L. Engsig M.T. Lou H. Ferreras M. Lochter A. Delaisse J.M. Foged N.T. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis J. Biol. Chem. 2002 277 44061 44067 10.1074/jbc.M207205200 12226090 · DOI
  35. [36]Kollet O. Dar A. Shivtiel S. Kalinkovich A. Lapid K. Sztainberg Y. Tesio M. Samstein R.M. Goichberg P. Spiegel A. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells Nat. Med. 2006 12 657 664 10.1038/nm1417 16715089 · DOI
  36. [37]Everts V. Delaisse J.M. Korper W. Jansen D.C. Tigchelaar-Gutter W. Saftig P. Beertsen W. The bone lining cell: Its role in cleaning Howship’s lacunae and initiating bone formation J. Bone Miner. Res. 2002 17 77 90 10.1359/jbmr.2002.17.1.77 11771672 · DOI · Paper page
  37. [38]Ominsky M.S. Niu Q.T. Li C.Y. Li X.D. Ke H.Z. Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody J. Bone Miner. Res. 2014 29 1424 1430 10.1002/jbmr.2152 24967455 · DOI · Paper page
  38. [39]Kim S.W. Lu Y.H. Williams E.A. Lai F. Lee J.Y. Enishi T. Balani D.H. Ominsky M.S. Ke H.Z. Kronenberg H.M. Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts J. Bone Miner. Res. 2017 32 892 901 10.1002/jbmr.3038 27862326 PMC5413385 · DOI
  39. [40]Irie K. Ejiri S. Sakakura Y. Shibui T. Yajima T. Matrix mineralization as a trigger for osteocyte maturation J. Histochem. Cytochem. 2008 56 561 567 10.1369/jhc.2008.950527 18319272 PMC2386767 · DOI
  40. [41]Genetos D.C. Yellowley C.E. Loots G.G. Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression PLoS ONE 2011 6 e17772 10.1371/journal.pone.0017772 21436889 PMC3059227 · DOI
  41. [42]Winkler D.G. Sutherland M.K. Geoghegan J.C. Yu C. Hayes T. Skonier J.E. Shpektor D. Jonas M. Kovacevich B.R. Staehling-Hampton K. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist Embo J. 2003 22 6267 6276 10.1093/emboj/cdg599 14633986 PMC291840 · DOI
  42. [43]Kogawa M. Wijenayaka A.R. Ormsby R.T. Thomas G.P. Anderson P.H. Bonewald L.F. Findlay D.M. Atkins G.J. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2 J. Bone Miner. Res. 2013 28 2436 2448 10.1002/jbmr.2003 23737439 · DOI
  43. [44]Qing H. Ardeshirpour L. Pajevic P.D. Dusevich V. Jahn K. Kato S. Wysolmerski J. Bonewald L.F. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation J. Bone Miner. Res. 2012 27 1018 1029 10.1002/jbmr.1567 22308018 PMC3770147 · DOI · Paper page
  44. [45]Tsourdi E. Jahn K. Rauner M. Busse B. Bonewald L.F. Physiological and pathological osteocytic osteolysis J. Musculoskelet Neuronal Interact. 2018 18 292 303 30179206 PMC6146198
  45. [46]Wei W. Zeve D. Suh J.M. Wang X. Du Y. Zerwekh J.E. Dechow P.C. Graff J.M. Wan Y. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin Mol. Cell Biol. 2011 31 4706 4719 10.1128/MCB.05980-11 21876000 PMC3232928 · DOI
  46. [47]Wijenayaka A.R. Kogawa M. Lim H.P. Bonewald L.F. Findlay D.M. Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway PLoS ONE 2011 6 e25900 10.1371/journal.pone.0025900 21991382 PMC3186800 · DOI · Paper page
  47. [48]Weivoda M.M. Ruan M. Hachfeld C.M. Pederson L. Howe A. Davey R.A. Zajac J.D. Kobayashi Y. Williams B.O. Westendorf J.J. Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways J. Bone Miner. Res. 2016 31 65 75 10.1002/jbmr.2599 26189772 PMC4758681 · DOI
  48. [49]Holmen S.L. Zylstra C.R. Mukherjee A. Sigler R.E. Faugere M.C. Bouxsein M.L. Deng L.F. Clemens T.L. Williams B.O. Essential role of beta-catenin in postnatal bone acquisition J. Biol. Chem. 2005 280 21162 21168 10.1074/jbc.M501900200 15802266 · DOI · Paper page
  49. [50]Giachelli C.M. Ectopic calcification: Gathering hard facts about soft tissue mineralization Am. J. Pathol. 1999 154 671 675 10.1016/S0002-9440(10)65313-8 10079244 PMC1866412 · DOI
  50. [51]Shanahan C.M. Crouthamel M.H. Kapustin A. Giachelli C.M. Arterial Calcification in Chronic Kidney Disease: Key Roles for Calcium and Phosphate Circ. Res. 2011 109 697 711 10.1161/CIRCRESAHA.110.234914 21885837 PMC3249146 · DOI
  51. [52]Neven E. De Schutter T.M. De Broe M.E. D’Haese P.C. Cell biological and physicochemical aspects of arterial calcification Kidney Int. 2011 79 1166 1177 10.1038/ki.2011.59 21412217 · DOI
  52. [53]Neven E. Persy V. Dauwe S. De Schutter T. De Broe M.E. D’Haese P.C. Chondrocyte Rather Than Osteoblast Conversion of Vascular Cells Underlies Medial Calcification in Uremic Rats Arterioscl Throm Vas 2010 30 1741 1750 10.1161/ATVBAHA.110.204834 20522801 · DOI
  53. [54]Barrett H.E. Van der Heiden K. Farrell E. Gijsen F.J.H. Akyildiz A.C. Calcifications in atherosclerotic plaques and impact on plaque biomechanics J. Biomech. 2019 87 1 12 10.1016/j.jbiomech.2019.03.005 30904335 · DOI
  54. [55]Goodwin A.M. Sullivan K.M. D’Amore P.A. Cultured endothelial cells display endogenous activation of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signaling Dev. Dyn. 2006 235 3110 3120 10.1002/dvdy.20939 17013885 · DOI
  55. [56]Goodwin A.M. Kitajewski J. D’Amore P.A. Wnt1 and Wnt5a affect endothelial proliferation and capillary length; Wnt2 does not Growth Factors 2007 25 25 32 10.1080/08977190701272933 17454147 · DOI
  56. [57]Wright M. Aikawa M. Szeto W. Papkoff J. Identification of a Wnt-responsive signal transduction pathway in primary endothelial cells Biochem Biophys Res. Commun. 1999 263 384 388 10.1006/bbrc.1999.1344 10491302 · DOI
  57. [58]Kim J. Kim J. Kim D.W. Ha Y. Ihm M.H. Kim H. Song K. Lee I. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling J. Immunol. 2010 185 1274 1282 10.4049/jimmunol.1000181 20554957 · DOI
  58. [59]Vikram A. Kim Y.R. Kumar S. Naqvi A. Hoffman T.A. Kumar A. Miller F.J. Jr. Kim C.S. Irani K. Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species Arterioscler Thromb Vasc. Biol. 2014 34 2301 2309 10.1161/ATVBAHA.114.304338 25147340 PMC6069972 · DOI
  59. [60]Wang F. Liu Z. Park S.H. Gwag T. Lu W. Ma M. Sui Y. Zhou C. Myeloid beta-Catenin Deficiency Exacerbates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler Thromb Vasc. Biol. 2018 38 1468 1478 10.1161/ATVBAHA.118.311059 29724817 PMC6023740 · DOI
  60. [61]Schaale K. Neumann J. Schneider D. Ehlers S. Reiling N. Wnt signaling in macrophages: Augmenting and inhibiting mycobacteria-induced inflammatory responses Eur. J. Cell Biol. 2011 90 553 559 10.1016/j.ejcb.2010.11.004 21185106 · DOI
  61. [62]Borrell-Pages M. Romero J.C. Badimon L. Cholesterol modulates LRP5 expression in the vessel wall Atherosclerosis 2014 235 363 370 10.1016/j.atherosclerosis.2014.05.922 24929284 · DOI
  62. [63]Magoori K. Kang M.J. Ito M.R. Kakuuchi H. Ioka R.X. Kamataki A. Kim D.H. Asaba H. Iwasaki S. Takei Y.A. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E J. Biol. Chem. 2003 278 11331 11336 10.1074/jbc.M211987200 12509421 · DOI
  63. [64]Marchand A. Atassi F. Gaaya A. Leprince P. Le Feuvre C. Soubrier F. Lompre A.M. Nadaud S. The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans Aging Cell 2011 10 220 232 10.1111/j.1474-9726.2010.00661.x 21108734 · DOI
  64. [65]Ezan J. Leroux L. Barandon L. Dufourcq P. Jaspard W. Moreau C. Allieres C. Daret D. Couffinhal T. Duplaa C. FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo Cardiovasc Res. 2004 63 731 738 10.1016/j.cardiores.2004.05.006 15306229 · DOI
  65. [66]Leto G. D’Onofrio L. Lucantoni F. Zampetti S. Campagna G. Foffi C. Moretti C. Carlone A. Palermo A. Leopizzi M. Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy Diabetes Metab Res. 2019 35 e3069 10.1002/dmrr.3069 30144272 · DOI
  66. [67]Morales-Santana S. Garcia-Fontana B. Garcia-Martin A. Rozas-Moreno P. Garcia-Salcedo J.A. Reyes-Garcia R. Munoz-Torres M. Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels Diabetes Care 2013 36 1667 1674 10.2337/dc12-1691 23288857 PMC3661830 · DOI
  67. [68]Krishna S.M. Seto S.W. Jose R.J. Li J. Morton S.K. Biros E. Wang Y. Nsengiyumva V. Lindeman J.H.N. Loots G.G. Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis Arterioscl Throm Vas 2017 37 553 10.1161/ATVBAHA.116.308723 28062506 · DOI
  68. [69]Nakamura S. Ishibashi-Ueda H. Niizuma S. Yoshihara F. Horio T. Kawano Y. Coronary Calcification in Patients with Chronic Kidney Disease and Coronary Artery Disease Clin. J. Am. Soc. Nephro 2009 4 1892 1900 10.2215/CJN.04320709 PMC2798876 19833908 · DOI
  69. [70]Saxena A. Waddell I.C. Friesen R.W. Michalski R.T. Monckeberg medial calcific sclerosis mimicking malignant calcification pattern at mammography J. Clin. Pathol. 2005 58 447 448 PMC1770620 15790721
  70. [71]Castillo B.V. Torczynski E. Edward D.P. Monckeberg’s sclerosis in temporal artery biopsy specimens Brit. J. Ophthalmol. 1999 83 1091 1092 10.1136/bjo.83.9.e1088 10636687 PMC1723181 · DOI
  71. [72]Liu J.Y. Zhang L. Zhou Y. Zhu D. Wang Q. Hao L.R. Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease Int. Urol. Nephrol. 2016 48 1313 1319 10.1007/s11255-016-1291-2 27156072 · DOI
  72. [73]He F. Wang H. Ren W.Y. Ma Y. Liao Y.P. Zhu J.H. Cui J. Deng Z.L. Su Y.X. Gan H. BMP9/COX-2 axial mediates high phosphate-induced calcification in vascular smooth muscle cells via Wnt/beta-catenin pathway J. Cell. Biochem. 2018 119 2851 2863 10.1002/jcb.26460 29073723 · DOI
  73. [74]Jin X.C. Rong S. Yuan W.J. Gu L.J. Jia J.S. Wang L. Yu H.L. Zhuge Y.F. Frontiers in Physiology High Mobility Group Box 1 Promotes Aortic Calcification in Chronic Kidney Disease via the Wnt/beta-Catenin Pathway Front. Physiol. 2018 9 665 10.3389/fphys.2018.00665 29922171 PMC5996195 · DOI
  74. [75]Zhang H. Chen J. Shen Z. Gu Y. Xu L. Hu J. Zhang X. Ding X. Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/beta-catenin signaling Toxicol. Lett. 2018 284 29 36 10.1016/j.toxlet.2017.11.033 29195902 · DOI
  75. [76]Deng D. Diao Z. Han X. Liu W. Secreted Frizzled-Related Protein 5 Attenuates High Phosphate-Induced Calcification in Vascular Smooth Muscle Cells by Inhibiting the Wnt/ss-Catenin Pathway Calcif. Tissue Int. 2016 99 66 75 10.1007/s00223-016-0117-7 26895007 · DOI
  76. [77]Tian B.Y. Yao L. Sheng Z.T. Wan P.Z. Qiu X.B. Wang J. Xu T.H. Specific knockdown of WNT8b expression protects against phosphate-induced calcification in vascular smooth muscle cells by inhibiting the Wnt-beta-catenin signaling pathway J. Cell Physiol. 2019 234 3469 3477 10.1002/jcp.26827 30461014 · DOI
  77. [78]Rong S. Zhao X.Z. Jin X.C. Zhang Z. Chen L. Zhu Y.X. Yuan W.J. Vascular Calcification in Chronic Kidney Disease is Induced by Bone Morphogenetic Protein-2 via a Mechanism Involving the Wnt/beta-Catenin Pathway Cell Physiol. Biochem. 2014 34 2049 2060 10.1159/000366400 25562153 · DOI
  78. [79]Freise C. Kretzschmar N. Querfeld U. Wnt signaling contributes to vascular calcification by induction of matrix metalloproteinases BMC Cardiovasc Disor. 2016 16 185 10.1186/s12872-016-0362-8 PMC5045611 27716072 · DOI
  79. [80]Liao R.X. Wang L.Y. Li J.M. Xiong Y.Q. Li Y.P. Han M. Jiang H. Anil M. Su B.H. Vascular Calcification Is Associated with Wnt-Signaling Pathway and Blood Pressure Variability in Chronic Kidney Disease Rats Nephrol Dial. Transpl. 2019 34 10.1093/ndt/gfz101.SaO049 31709686 · DOI
  80. [81]Nie B. Zhang S.Y. Guan S.M. Zhou S.Q. Fang X. Role of Wnt/beta-Catenin Pathway in the Arterial Medial Calcification and Its Effect on the OPG/RANKL System Curr Med. Sci. 2019 39 28 36 10.1007/s11596-019-1996-4 30868488 · DOI
  81. [82]Faverman L. Mikhaylova L. Malmquist J. Nurminskaya M. Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells Febs Lett. 2008 582 1552 1557 10.1016/j.febslet.2008.03.053 18405667 · DOI
  82. [83]Zeadin M.G. Butcher M.K. Shaughnessy S.G. Werstuck G.H. Leptin promotes osteoblast differentiation and mineralization of primary cultures of vascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3 beta Biochem. Bioph. Res. Co 2012 425 924 930 10.1016/j.bbrc.2012.08.011 22906741 · DOI
  83. [84]Wang Y.Y. Shan J.G. Yang W.G. Zheng H. Xue S. High Mobility Group Box 1 (HMGB1) Mediates High-Glucose-Induced Calcification in Vascular Smooth Muscle Cells of Saphenous Veins Inflammation 2013 36 1592 1604 10.1007/s10753-013-9704-1 23928875 · DOI
  84. [85]Shao J.S. Cheng S.L. Pingsterhaus J.M. Charlton-Kachigian N. Loewy A.R. Towler D.A. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals J. Clin. Investig. 2005 115 1210 1220 10.1172/JCI24140 15841209 PMC1077175 · DOI
  85. [86]Cai T. Sun D.Q. Duan Y. Wen P. Dai C.S. Yang J.W. He W.C. WNT/beta-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression Exp. Cell Res. 2016 345 206 217 10.1016/j.yexcr.2016.06.007 27321958 · DOI
  86. [87]De Mare A. Maudsley S. Azmi A. Hendrickx J.O. Opdebeeck B. Neven E. D’Haese P.C. Verhulst A. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis Toxins 2019 11 428 10.3390/toxins11070428 PMC6669501 31330917 · DOI
  87. [88]Wang J. Qiu X.B. Xu T.H. Sheng Z.T. Yao L. Sclerostin/Receptor Related Protein 4 and Ginkgo Biloba Extract Alleviates beta-Glycerophosphate-Induced Vascular Smooth Muscle Cell Calcification By Inhibiting Wnt/beta-Catenin Pathway Blood Purificat 2019 47 17 23 10.1159/000496219 PMC6518869 30699436 · DOI
  88. [89]De Oca A.M. Guerrero F. Martinez-Moreno J.M. Madueno J.A. Herencia C. Peralta A. Almaden Y. Lopez I. Aguilera-Tejero E. Gundlach K. Magnesium Inhibits Wnt/beta-Catenin Activity and Reverses the Osteogenic Transformation of Vascular Smooth Muscle Cells PLoS ONE 2014 9 e89525 10.1371/journal.pone.0089525 24586847 PMC3934896 · DOI
  89. [90]Herencia C. Rodriguez-Ortiz M.E. Munoz-Castaneda J.R. Martinez-Moreno J.M. Canalejo R. Montes de Oca A. Diaz-Tocados J.M. Peralbo-Santaella E. Marin C. Canalejo A. Angiotensin II prevents calcification in vascular smooth muscle cells by enhancing magnesium influx Eur. J. Clin. Investig. 2015 45 1129 1144 10.1111/eci.12517 26268950 · DOI
  90. [91]Chen T.L. Mao H.J. Chen C. Wu L. Wang N.N. Zhao X.F. Qian J. Xing C.Y. The Role and Mechanism of alpha-Klotho in the Calcification of Rat Aortic Vascular Smooth Muscle Cells Biomed. Res. Int. 2015 194362 10.1155/2015/194362 26609522 PMC4644825 · DOI
  91. [92]Saito Y. Nakamura K. Miura D. Yunoki K. Miyoshi T. Yoshida M. Kawakita N. Kimura T. Kondo M. Sarashina T. Suppression of Wnt Signaling and Osteogenic Changes in Vascular Smooth Muscle Cells by Eicosapentaenoic Acid Nutrients 2017 9 858 10.3390/nu9080858 28796175 PMC5579651 · DOI
  92. [93]Gao M. Chen T.L. Wu L. Zhao X.F. Mao H.J. Xing C.Y. Effect of pioglitazone on the calcification of rat vascular smooth muscle cells through the downregulation of the Wnt/beta-catenin signaling pathway Mol. Med. Rep. 2017 16 6208 6213 10.3892/mmr.2017.7308 28849074 · DOI
  93. [94]Freise C. Bobb V. Querfeld U. Collagen XIV and a related recombinant fragment protect human vascular smooth muscle cells from calcium-/phosphate-induced osteochondrocytic transdifferentiation Exp. Cell Res. 2017 358 242 252 10.1016/j.yexcr.2017.06.018 28655510 · DOI
  94. [95]Guo Y. Bao S.M. Guo W. Diao Z.L. Wang L.Y. Han X. Guo W.K. Liu W.H. Bone marrow mesenchymal stem cell-derived exosomes alleviate high phosphorus-induced vascular smooth muscle cells calcification by modifying microRNA profiles Funct Integr. Genom. 2019 19 633 643 10.1007/s10142-019-00669-0 30850904 · DOI
  95. [96]Chaturvedi P. Chen N.X. O’Neill K. McClintick J.N. Moe S.M. Janga S.C. Differential miRNA Expression in Cells and Matrix Vesicles in Vascular Smooth Muscle Cells from Rats with Kidney Disease PLoS ONE 2015 10 e0131589 10.1371/journal.pone.0131589 26115487 PMC4482652 · DOI
  96. [97]Cheng S.L. Shao J.S. Halstead L.R. Distelhorst K. Sierra O. Towler D.A. Activation of Vascular Smooth Muscle Parathyroid Hormone Receptor Inhibits Wnt/beta-Catenin Signaling and Aortic Fibrosis in Diabetic Arteriosclerosis Circ. Res. 2010 107 271 10.1161/CIRCRESAHA.110.219899 20489161 PMC2913587 · DOI
  97. [98]Zhang P. Li Y. Du Y. Li G. Wang L. Zhou F. Resveratrol Ameliorated Vascular Calcification by Regulating Sirt-1 and Nrf2 Transpl. P 2016 48 3378 3386 10.1016/j.transproceed.2016.10.023 27931585 · DOI
  98. [99]Bartoli-Leonard F. Wilkinson F.L. Langford-Smith A.W.W. Alexander M.Y. Weston R. The Interplay of SIRT1 and Wnt Signaling in Vascular Calcification Front. Cardiovasc Med. 2018 5 183 10.3389/fcvm.2018.00183 30619890 PMC6305318 · DOI
  99. [100]Choi S.Y. Ryu H.M. Oh E.J. Choi J.Y. Cho J.H. Kim C.D. Kim Y.L. Park S.H. Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells PLoS ONE 2017 12 e0180393 10.1371/journal.pone.0180393 28686724 PMC5501516 · DOI
  100. [101]Shalhoub V. Shatzen E. Henley C. Boedigheimer M. McNinch J. Manoukian R. Damore M. Fitzpatrick D. Haas K. Twomey B. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols Calcif. Tissue Int. 2006 79 431 442 10.1007/s00223-006-0126-z 17171500 · DOI
  101. [102]Martinez-Moreno J.M. Munoz-Castaneda J.R. Herencia C. de Oca A.M. Estepa J.C. Canalejo R. Rodriguez-Ortiz M.E. Perez-Martinez P. Aguilera-Tejero E. Canalejo A. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation Am. J. Physiol. Renal 2012 303 F1136 F1144 10.1152/ajprenal.00684.2011 22874762 · DOI
  102. [103]Pelletier S. Dubourg L. Carlier M.C. Hadj-Aissa A. Fouque D. The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD Clin. J. Am. Soc. Nephro 2013 8 819 823 10.2215/CJN.07670712 23430206 PMC3641616 · DOI
  103. [104]Cejka D. Jager-Lansky A. Kieweg H. Weber M. Bieglmayer C. Haider D.G. Diarra D. Patsch J.M. Kainberger F. Bohle B. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients Nephrol Dial. Transpl. 2012 27 226 230 10.1093/ndt/gfr270 21613383 · DOI
  104. [105]Cejka D. Marculescu R. Kozakowski N. Plischke M. Reiter T. Gessl A. Haas M. Renal Elimination of Sclerostin Increases With Declining Kidney Function J. Clin. Endocr. Metab. 2014 99 248 255 10.1210/jc.2013-2786 24187403 · DOI
  105. [106]Sabbagh Y. Graciolli F.G. O’Brien S. Tang W. dos Reis L.M. Ryan S. Phillips L. Boulanger J. Song W.P. Bracken C. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy J. Bone Miner. Res. 2012 27 1757 1772 10.1002/jbmr.1630 22492547 · DOI
  106. [107]Qureshi A.R. Olauson H. Witasp A. Haarhaus M. Brandenburg V. Wernerson A. Lindholm B. Soderberg M. Wennberg L. Nordfors L. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification Kidney Int. 2015 88 1356 1364 10.1038/ki.2015.194 26331407 · DOI
  107. [108]Bisson S.K. Ung R.V. Picard S. Valade D. Agharazii M. Lariviere R. Mac-Way F. High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats J. Bone Miner. Metab 2019 37 212 223 10.1007/s00774-018-0919-y 29603070 · DOI
  108. [109]Carrillo-Lopez N. Panizo S. Alonso-Montes C. Martinez-Arias L. Avello N. Sosa P. Dusso A.S. Cannata-Andia J.B. Naves-Diaz M. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease Nephrol Dial. Transpl. 2019 34 934 941 10.1093/ndt/gfy287 30189026 · DOI
  109. [110]Kramann R. Brandenburg V.M. Schurgers L.J. Ketteler M. Westphal S. Leisten I. Bovi M. Jahnen-Dechent W. Knuchel R. Floege J. Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy Nephrol Dial. Transpl. 2013 28 856 868 10.1093/ndt/gfs466 23223222 · DOI
  110. [111]Brandenburg V.M. Kramann R. Rothe H. Kaesler N. Korbiel J. Specht P. Schmitz S. Kruger T. Floege J. Ketteler M. Calcific uraemic arteriolopathy (calciphylaxis): Data from a large nationwide registry Nephrol Dial. Transpl. 2017 32 126 132 10.1093/ndt/gfv438 26908770 · DOI
  111. [112]Ho T.Y. Chen N.C. Hsu C.Y. Huang C.W. Lee P.T. Chou K.J. Fang H.C. Chen C.L. Evaluation of the association of Wnt signaling with coronary artery calcification in patients on dialysis with severe secondary hyperparathyroidism BMC Nephrol. 2019 20 345 10.1186/s12882-019-1543-3 31477034 PMC6721332 · DOI
  112. [113]Kuipers A.L. Miljkovic I. Carr J.J. Terry J.G. Nestlerode C.S. Ge Y.R. Bunker C.H. Patrick A.L. Zmuda J.M. Association of circulating sclerostin with vascular calcification in Afro-Caribbean men Atherosclerosis 2015 239 218 223 10.1016/j.atherosclerosis.2015.01.010 25618029 PMC4331206 · DOI
  113. [114]Morena M. Jaussent I. Dupuy A.M. Bargnoux A.S. Kuster N. Chenine L. Leray-Moragues H. Klouche K. Vernhet H. Canaud B. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: Potential partners in vascular calcifications Nephrol. Dial. Transpl. 2015 30 1345 1356 10.1093/ndt/gfv081 25854266 · DOI
  114. [115]Pelletier S. Confavreux C.B. Haesebaert J. Guebre-Egziabher F. Bacchetta J. Carlier M.C. Chardon L. Laville M. Chapurlat R. London G.M. Serum sclerostin: The missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos. Int. 2015 26 2165 2174 10.1007/s00198-015-3127-9 25910747 · DOI
  115. [116]Lee Y.T. Ng H.Y. Chiu T.T.Y. Li L.C. Pei S.N. Kuo W.H. Lee C.T. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients Clin. Chim. Acta 2016 452 38 43 10.1016/j.cca.2015.10.031 26522655 · DOI
  116. [117]Lv W. Guan L.N. Zhang Y. Yu S.Q. Cao B.F. Ji Y.Q. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4 Int. Urol. Nephrol. 2016 48 2043 2050 10.1007/s11255-016-1379-8 27465794 · DOI
  117. [118]Jorgensen H.S. Winther S. Dupont L. Bottcher M. Rejnmark L. Hauge E.M. Svensson M. Ivarsen P. Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates Clin. Nephrol. 2018 90 18 26 10.5414/CN109333 29701175 · DOI
  118. [119]Yang C.Y. Chang Z.F. Chau Y.P. Chen A. Yang W.C. Yang A.H. Lee O.K.S. Circulating Wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications Nephrol. Dial. Transpl. 2015 30 1356 1363 10.1093/ndt/gfv043 25817223 · DOI
  119. [120]Evenepoel P. Goffin E. Meijers B. Kanaan N. Bammens B. Coche E. Claes K. Jadoul M. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients J. Clin. Endocr. Metab. 2015 100 4669 4676 10.1210/jc.2015-3056 26505822 · DOI
  120. [121]Borawski J. Zoltko J. Labij-Reduta B. Koc-Zorawska E. Naumnik B. Effects of Enoxaparin on Intravascular Sclerostin Release in Healthy Men J. Cardiovasc. Pharm T 2018 23 344 349 10.1177/1074248418770623 29658328 · DOI
  121. [122]De Mare A. Verhulst A. Cavalier E. Delanaye P. Behets G.J. Meijers B. Kuypers D. D’Haese P.C. Evenepoel P. Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease J. Clin. Med. 2019 8 2027 10.3390/jcm8122027 31756992 PMC6947521 · DOI
  122. [123]Delanaye P. Paquot F. Bouquegneau A. Blocki F. Krzesinski J.M. Evenepoel P. Pottel H. Cavalier E. Sclerostin and chronic kidney disease: The assay impacts what we (thought to) know Nephrol. Dial. Transpl. 2018 33 1404 1410 10.1093/ndt/gfx282 29048521 · DOI
  123. [124]Piec I. Washbourne C. Tang J. Fisher E. Greeves J. Jackson S. Fraser W.D. How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits Calcif. Tissue Int. 2016 98 546 555 10.1007/s00223-015-0105-3 26749312 PMC4860200 · DOI
  124. [125]Sato M. Hanafusa N. Kawaguchi H. Tsuchiya K. Nitta K. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients Kidney Blood Press R 2018 43 1023 1033 10.1159/000490824 29940587 · DOI
  125. [126]Nowak A. Artunc F. Serra A.L. Pollock E. Krayenbuhl P.A. Muller C. Friedrich B. Sclerostin Quo Vadis?—Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients? Kidney Blood Press R 2015 40 266 276 10.1159/000368502 25997652 · DOI
  126. [127]Delanaye P. Krzesinski J.M. Warling X. Moonen M. Smelten N. Medart L. Bruyere O. Reginster J.Y. Pottel H. Cavalier E. Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients Nephron Clin. Pract. 2014 128 127 134 10.1159/000366449 25377055 · DOI
  127. [128]Goncalves F.L.C. Elias R.M. dos Reis L.M. Graciolli F.G. Zampieri F.G. Oliveira R.B. Jorgetti V. Moyses R.M.A. Serum sclerostin is an independent predictor of mortality in hemodialysis patients BMC Nephrol. 2014 15 190 10.1186/1471-2369-15-190 25465028 PMC4265422 · DOI
  128. [129]Drechsler C. Evenepoel P. Vervloet M.G. Wanner C. Ketteler M. Marx N. Floege J. Dekker F.W. Brandenburg V.M. Grp N.S. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: Results from the NECOSAD study Nephrol Dial. Transpl. 2015 30 288 293 10.1093/ndt/gfu301 25248363 · DOI
  129. [130]Jean G. Chazot C. Bresson E. Zaoui E. Cavalier E. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients Nephron 2016 132 181 190 10.1159/000443845 26890570 · DOI
  130. [131]Wang X.R. Yuan L.A. Zhang J.J. Hao L. Wang D.G. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D Nephrology 2017 22 286 292 10.1111/nep.12813 27165564 · DOI
  131. [132]Lips L. van Zuijdewijn C.L.M.D. Ter Wee P.M. Bots M.L. Blankestijn P.J. van den Dorpel M.A. Fouque D. de Jongh R. Pelletier S. Vervloet M.G. Serum sclerostin: Relation with mortality and impact of hemodiafiltration Nephrol. Dial. Transpl. 2017 32 1217 1223 10.1093/ndt/gfw246 27342581 · DOI
  132. [133]Persy V. D’Haese P. Vascular calcification and bone disease: The calcification paradox Trends Mol. Med. 2009 15 405 416 10.1016/j.molmed.2009.07.001 19733120 · DOI
  133. [134]Viaene L. Behets G.J. Claes K. Meijers B. Blocki F. Brandenburg V. Evenepoel P. D’Haese P.C. Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial. Transpl. 2013 28 3024 3030 10.1093/ndt/gft039 23605174 · DOI
  134. [135]Rattazzi M. Bertacco E. Del Vecchio A. Puato M. Faggin E. Pauletto P. Aortic valve calcification in chronic kidney disease Nephrol. Dial. Transpl. 2013 28 2968 2976 10.1093/ndt/gft310 24097800 · DOI
  135. [136]Gu G.J. Chen T. Zhou H.M. Sun K.X. Li J. Role of Wnt/beta-catenin signaling pathway in the mechanism of calcification of aortic valve J. Huazhong Univ. Sci. Technol. Med. Sci. 2014 34 33 36 10.1007/s11596-014-1228-x 24496676 · DOI
  136. [137]Brandenburg V.M. Kramann R. Koos R. Kruger T. Schurgers L. Muhlenbruch G. Hubner S. Gladziwa U. Drechsler C. Ketteler M. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: A cross-sectional study BMC Nephrol. 2013 14 219 10.1186/1471-2369-14-219 24112318 PMC3851854 · DOI
  137. [138]Koos R. Brandenburg V. Mahnken A.H. Schneider R. Dohmen G. Autschbach R. Marx N. Kramann R. Sclerostin as a Potential Novel Biomarker for Aortic Valve J. Heart Valve Dis 2013 22 317 325 10.1016/S0735-1097(12)62008-7 24151757 · DOI
  138. [139]Ji Y.Q. Guan L.N. Yu S.X. Yin P.Y. Shen X.Q. Sun Z.W. Liu J. Lv W. Yu G.P. Ren C. Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease Eur Rev. Med. Pharmaco 2018 22 8822 8829 30575924
  139. [140]Munroe P.B. Olgunturk R.O. Fryns J.P. Van Maldergem L. Ziereisen F. Yuksel B. Gardiner R.M. Chung E. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome Nat. Genet. 1999 21 142 144 10.1038/5102 9916809 · DOI
  140. [141]Rutsch F. Ruf N. Vaingankar S. Toliat M.R. Suk A. Hohne W. Schauer G. Lehmann M. Roscioli T. Schnabel D. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification Nat. Genet. 2003 34 379 381 10.1038/ng1221 12881724 · DOI
  141. [142]Nitschke Y. Baujat G. Botschen U. Wittkampf T. du Moulin M. Stella J. Le Merrer M. Guest G. Lambot K. Tazarourte-Pinturier M.F. Generalized Arterial Calcification of Infancy and Pseudoxanthoma Elasticum Can Be Caused by Mutations in Either ENPP1 or ABCC6 Am. J. Hum. Genet. 2012 90 25 39 10.1016/j.ajhg.2011.11.020 22209248 PMC3257960 · DOI
  142. [143]Pendleton A. Johnson M.D. Hughes A. Gurley K.A. Ho A.M. Doherty M. Dixey J. Gillet P. Loeuille D. McGrath R. Mutations in ANKH cause chondrocalcinosis Am. J. Hum. Genet. 2002 71 933 940 10.1086/343054 12297987 PMC378546 · DOI
  143. [144]St Hilaire C. Ziegler S.G. Markello T.C. Brusco A. Groden C. Gill F. Carlson-Donohoe H. Lederman R.J. Chen M.Y. Yang D. NT5E Mutations and Arterial Calcifications N. Engl. J. Med. 2011 364 432 442 10.1056/NEJMoa0912923 21288095 PMC3049958 · DOI
  144. [145]Rafaelsen S. Johansson S. Raeder H. Bjerknes R. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature BMC Genet. 2014 15 10.1186/s12863-014-0098-3 25249269 PMC4181413 · DOI
  145. [146]Hsu S.C. Sears R.L. Lemos R.R. Quintans B. Huang A. Spiteri E. Nevarez L. Mamah C. Zatz M. Pierce K.D. Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification Neurogenetics 2013 14 11 22 10.1007/s10048-012-0349-2 23334463 PMC4023541 · DOI
  146. [147]Zarb Y. Weber-Stadlbauer U. Kirschenbaum D. Kindler D.R. Richetto J. Keller D. Rademakers R. Dickson D.W. Pasch A. Byzova T. Ossified blood vessels in primary familial brain calcification elicit a neurotoxic astrocyte response Brain 2019 142 885 902 10.1093/brain/awz032 30805583 PMC6439320 · DOI
  147. [148]Bellahcene A. Castronovo V. Expression of bone matrix proteins in human breast cancer: Potential roles in microcalcification formation and in the genesis of bone metastases Bull. Cancer 1997 84 17 24 9180854
  148. [149]Grewal R.G. Austin J.H. CT demonstration of calcification in carcinoma of the lung J. Comput. Assist. Tomogr. 1994 18 867 871 10.1097/00004728-199411000-00004 7962791 · DOI
  149. [150]Kakkos S.K. Scopa C.D. Chalmoukis A.K. Karachalios D.A. Spiliotis J.D. Harkoftakis J.G. Karavias D.D. Androulakis J.A. Vagenakis A.G. Relative risk of cancer in sonographically detected thyroid nodules with calcifications J. Clin. Ultrasound 2000 28 347 352 10.1002/1097-0096(200009)28:7<347::AID-JCU5>3.0.CO;2-O 10934334 · DOI
  150. [151]Klimas R. Bennett B. Gardner W.A. Jr. Prostatic calculi: A review Prostate 1985 7 91 96 10.1002/pros.2990070110 3909127 · DOI
  151. [152]Livingston J.H. Stivaros S. Warren D. Crow Y.J. Intracranial calcification in childhood: A review of aetiologies and recognizable phenotypes Dev. Med. Child. Neurol. 2014 56 612 626 10.1111/dmcn.12359 24372060 · DOI
  152. [153]Lemos R.R. Ferreira J.B. Keasey M.P. Oliveira J.R. An update on primary familial brain calcification Int Rev. Neurobiol. 2013 110 349 371 10.1016/B978-0-12-410502-7.00015-6 24209445 · DOI
  153. [154]Westenberger A. Balck A. Klein C. Primary familial brain calcifications: Genetic and clinical update Curr. Opin. Neurol. 2019 32 571 578 10.1097/WCO.0000000000000712 31157644 · DOI
  154. [155]Hassanein A.M. Glanz S.M. Kessler H.P. Eskin T.A. Liu C. Beta-catenin is expressed aberrantly in tumors expressing shadow cells—Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst Am. J. Clin. Pathol 2003 120 732 736 10.1309/EALEG7LD6W7167PX 14608900 · DOI
  155. [156]Juca C.E.B. Colli L.M. Martins C.S. Campanini M.L. Paixao B. Juca R.V. Saggioro F.P. de Oliveira R.S. Moreira A.C. Machado H.R. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas Horm Metab Res. 2018 50 575 581 10.1055/a-0593-5956 29625497 · DOI
  156. [157]Kaplon H. Muralidharan M. Schneider Z. Reichert J.M. Antibodies to watch in 2020 MAbs 2020 12 1703531 10.1080/19420862.2019.1703531 31847708 PMC6973335 · DOI
  157. [158]Brandenburg V.M. Verhulst A. Babler A. D’Haese P.C. Evenepoel P. Kaesler N. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol. Dial. Transpl. 2019 34 408 414 10.1093/ndt/gfy129 29846712 · DOI
  158. [159]Saag K.G. Petersen J. Brandi M.L. Karaplis A.C. Lorentzon M. Thomas T. Maddox J. Fan M. Meisner P.D. Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis N. Engl. J. Med. 2017 377 1417 1427 10.1056/NEJMoa1708322 28892457 · DOI · Paper page
  159. [160]Ukita M. Yamaguchi T. Ohata N. Tamura M. Sclerostin Enhances Adipocyte Differentiation in 3T3-L1 Cells J. Cell. Biochem. 2016 117 1419 1428 10.1002/jcb.25432 26553151 · DOI
  160. [161]Fairfield H. Falank C. Harris E. Demambro V. McDonald M. Pettitt J.A. Mohanty S.T. Croucher P. Kramer I. Kneissel M. The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis J. Cell Physiol. 2018 233 1156 1167 10.1002/jcp.25976 28460416 PMC5664178 · DOI
  161. [162]Beier E.E. Sheu T.J. Resseguie E.A. Takahata M. Awad H.A. Cory-Slechta D.A. Puzas J.E. Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice Bone Res. 2017 5 10.1038/boneres.2017.13 28529816 PMC5422922 · DOI
  162. [163]Kim S.P. Frey J.L. Li Z. Kushwaha P. Zoch M.L. Tomlinson R.E. Da H. Aja S. Noh H.L. Kim J.K. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes Proc. Natl. Acad. Sci. USA 2017 114 E11238 E11247 10.1073/pnas.1707876115 29229807 PMC5748171 · DOI
  163. [164]Cheng L.J. Zhang L. Yang J. Hao L.R. Activation of peroxisome proliferator-activated receptor gamma inhibits vascular calcification by upregulating Klotho Exp. Ther Med. 2017 13 467 474 10.3892/etm.2016.3996 28352317 PMC5348673 · DOI
  164. [165]Woldt E. Terrand J. Mlih M. Matz R.L. Bruban V. Coudane F. Foppolo S. El Asmar Z. Chollet M.E. Ninio E. The nuclear hormone receptor PPAR gamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells Nat. Commun. 2012 3 10.1038/ncomms2087 PMC3523725 23011131 · DOI
  165. [166]Chouinard L. Felx M. Mellal N. Varela A. Mann P. Jolette J. Samadfam R. Smith S.Y. Locher K. Buntich S. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study Regul. Toxicol Pharm. 2016 81 212 222 10.1016/j.yrtph.2016.08.010 27569204 · DOI
  166. [167]Ominsky M.S. Boyd S.K. Varela A. Jolette J. Felx M. Doyle N. Mellal N. Smith S.Y. Locher K. Buntich S. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys J. Bone Miner. Res. 2017 32 788 801 10.1002/jbmr.3036 27865001 · DOI
  167. [168]Pflanz D. Birkhold A.I. Albiol L. Thiele T. Julien C. Seliger A. Thomson E. Kramer I. Kneissel M. Duda G.N. Sost deficiency led to a greater cortical bone formation response to mechanical loading and altered gene expression Sci Rep. 2017 7 10.1038/s41598-017-09653-9 PMC5572735 28842678 · DOI
  168. [169]Van Lierop A.H. Moester M.J.C. Hamdy N.A.T. Papapoulos S.E. Serum Dickkopf 1 Levels in Sclerostin Deficiency J. Clin. Endocr. Metab. 2014 99 E252 E256 10.1210/jc.2013-3278 24302746 · DOI
  169. [170]Kang J.H. Keller J.J. Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: A 2-year follow-up study Osteoporosis Int. 2013 24 271 277 10.1007/s00198-012-2213-5 23152093 · DOI
  170. [171]Kim D.H. Rogers J.R. Fulchino L.A. Kim C.A. Solomon D.H. Kim S.C. Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis PLoS ONE 2015 10 10.1371/journal.pone.0122646 25884398 PMC4401508 · DOI
  171. [172]Kranenburg G. Bartstra J.W. Weijmans M. de Jong P.A. Mali W.P. Verhaar H.J. Visseren F.L.J. Spiering W. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis Atherosclerosis 2016 252 106 115 10.1016/j.atherosclerosis.2016.06.039 27513349 · DOI

Cited by

Sorted by citations

Authors
De Maré, A., D’Haese, P. C., & Verhulst, A.
Affiliations
  • Lab of Pathophysiology, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie Eiken, University of Antwerp, 2610 Antwerp, Belgium
  • University of Antwerp (BE)
Corresponding author
Verhulst, Anja
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-04-30
Volume
21
Issue
9
Pages
3199
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms21093199
PMC
PMC7246472
OpenAlex
W3023937761
Cited by
45
References
1
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 10 · 2021: 5 · 2020: 6
FWCI
1.11
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Fonds Wetenschappelijk Onderzoek (1182417N, 1182419N)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
  • Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
sclerostin, ectopic calcification, cardiovascular calcification, osteocytes, Wnt/β-catenin signaling, bone resorption, bone formation, chronic kidney disease, older adults
MeSH terms
Animals, Bone and Bones, Humans, Adaptor Proteins, Signal Transducing, Renal Insufficiency, Chronic, Wnt Signaling Pathway, Vascular Calcification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review